Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.

The Journal of antimicrobial chemotherapy - 1 Jul 2015

Charpentier Charlotte, Lee Guinevere Q, Rodriguez Christophe, Visseaux Benoit, Storto Alexandre, Fagard Catherine, Molina Jean-Michel, Katlama Christine, Yazdanpanah Yazdan, Harrigan P Richard, Descamps Diane

Abstract excerpt

OBJECTIVES: To assess the prevalence of minority resistant variants (MRVs) at baseline and their impact on the virological response. The ANRS 139 TRIO trial evaluated the combination of raltegravir, etravirine and darunavir, plus an optimized background therapy, in 87% of cases. Patients were highly experienced and harboured multiresistant viruses, but were naive to the three drugs, and showed a high level of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Reverse Transcriptase

Share to Nitriles

Share to Pyridazines

Share to Pyrimidines

Share to Raltegravir Potassium

Source

Identifiers

PMID: 25755001
DOI: 10.1093/jac/dkv048

Genes

TRIO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.PMID 25755001Read ↗

Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.Semantic proximity Read ↗

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.Semantic proximity Read ↗

Primary HIV-1 Drug Resistant Minority Variants.Semantic proximity Read ↗

Next-generation sequencing reveals major and minority HIV-1 drug resistance mutations in treatment-experienced individuals with virological failure.Semantic proximity Read ↗

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.Semantic proximity Read ↗

Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.Semantic proximity Read ↗

Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.Semantic proximity Read ↗

Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?Semantic proximity Read ↗

Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.Semantic proximity Read ↗

Minority resistant HIV-1 variants and the response to first-line NNRTI therapy.Semantic proximity Read ↗

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.Semantic proximity Read ↗

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.